Linnium Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-12-2024
- Paid Up Capital ₹ 0.50 M
as on 07-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
as on 07-12-2024
- Satisfied Charges ₹ 1.00 M
as on 07-12-2024
- Revenue 80.09%
(FY 2022)
- Profit 79.21%
(FY 2022)
- Ebitda 137.31%
(FY 2022)
- Net Worth 18.14%
(FY 2022)
- Total Assets 35.76%
(FY 2022)
About Linnium Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.00 M. The company has closed loans amounting to ₹1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Chhabi Bhattacharyya and Rajaram Banerjee serve as directors at the Company.
- CIN/LLPIN
U74999WB2016PTC216026
- Company No.
216026
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Hooghly, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Linnium Pharma Private Limited offer?
Linnium Pharma Private Limited offers a wide range of products and services, including Ayurvedic Digestive Medicine, Digestive Enzyme Syrup.
Who are the key members and board of directors at Linnium Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chhabi Bhattacharyya  | Director | 01-Jun-2016 | Current |
| Rajaram Banerjee | Director | 01-Jun-2016 | Current |
Financial Performance of Linnium Pharma.
Linnium Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 80.09% increase. The company also saw a substantial improvement in profitability, with a 79.21% increase in profit. The company's net worth Soared by an impressive increase of 18.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Linnium Pharma?
In 2020, Linnium Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 Mar 2022 | ₹3.00 M | Open |
Hdfc Bank Limited Creation Date: 24 Jul 2020 | ₹1.00 M | Satisfied |
How Many Employees Work at Linnium Pharma?
Linnium Pharma has a workforce of 26 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Linnium Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Linnium Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
